Tanta University
Tanta, Gharbia Governorate, 37515, Egypt
Completed
NCT Number: NCT06265389
Pentoxifylline as an Adjuvant Therapy in the Treatment of Pediatric Pneumonia; A New Perspective of an Old Drug
Pentoxifylline is a xanthine-derived, commercially produced drug approved for the management of intermittent claudication in patients suffering from a chronic occlusive arterial disease of the limbs. Pentoxifylline has been documented to display anti-inflammatory and immunomodulatory effects, as well as some antithrombotic and antiviral effects. This drug has also been shown to reduce lung fibrosis in patients with COVID-19, as well as to prevent thromboembolic events. This work aims to assess the benefit of oral Pentoxifyllin supplementation, in addition to standard antibiotic and other supportive therapy, in the management of hospitalized children with community-acquired pneumonia
Completed
Looking for future studies?
Notify MeKey information
Age range
2 month–18 year
Sex eligibility
All sexes
Study type
Interventional
Phase
Phase 4
Primary location
About this study
This is a randomized clinical trial study that will be carried out on 100 children with Community-acquired pneumonia admitted to the Pulmonology Unit, Pediatric department.
Group 1: Pentoxifylline group, and group 2: Control group
Who can participate
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
- All children aged 2 months -18 years with community-acquired pneumonia diagnosed by signs and symptoms of CAP including; chest pain, dyspnea, tachypnea, or abnormal auscultatory findings plus focal findings on chest x-ray indicating community-acquired pneumonia
Exclusion criteria
- Children with immunodeficiency, chronic lung disease, malignancy, congenital lung anomalies, underlying disorders impacting respiration i.e. genetic, metabolic, neuromuscular disorders, and children with CHD affecting the pulmonary blood flow.
Treatment and study plan
Pentoxifylline Oral Tablet
Drug50 children with community-acquired pneumonia will receive oral pentoxifylline in tablet form as an adjunct therapy to the usual pneumonia treatment for 5 days and the control group includes 50 children with community-acquired pneumonia with the standard pneumonia treatment.
Other names: TRENtal
Primary outcomes
-
Respiratory distress
Time frame: 3 days
Duration of improvement of respiratory distress
-
Temperature
Time frame: 3 days
Duration of defeverness
-
Oxygen saturation
Time frame: 3 days
Duration of normalization of hypoxia
-
CRP
Time frame: 5 days
Duration of normalization of CRP
-
LDH
Time frame: 5 days
Duration of normalization of LDH
-
D-dimer
Time frame: 5 days
Duration of normalization of D-dimer
-
Interleukin 6
Time frame: 5 days
Duration of normalization of IL-6
Secondary outcomes
-
Hospital stays
Time frame: 14 days
Duration of stay in hospital
-
Pneumonia complications
Time frame: 14 days
Occurrence of pneumonia complications
Other outcomes
-
Surgical intervention
Time frame: 14 days
Intercostal chest tube, bronchoscope, decortication, lobectomy
Sponsors and collaborators
Lead sponsor
Tanta University
Other
Registry information
Important dates
- Study start
- 2024
- Primary completion
- 2024
- Study completion
- 2025
- First posted
- Feb 20, 2024
- Registry last updated
- Jun 12, 2025
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.